Moberg Pharma Q1’21: Steady Progress

Research Note

2021-05-11

08:55

Redeye comments on the Q1 report. The company is still on track, and we expect the plan to submit the registration application in Europe in the second half of 2021 to hold. We do not see any surprises in the report with OPEX much in line with our expectations and a strong cash position.

MH

Mats Hyttinge

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.